Advertisement
The Hemo-Stream catheter, developed by Rex Medical, LP, is the firstchronic hemodialysis catheter specifically designed for over-the-wiredelivery. Its advantages include higher flow rates due to its triple lumendesign, reduced potential for air embolism or bleeding, decreased proceduralsteps and time versus competition, and ease of catheter placement. Dialysiscatheters, such as Hemo-Stream, are used for short term vascular access toprovide hemodialysis patients with the dialysis they require.
Advertisement
In April 2007, Angiotech entered into an agreement with Rex Medicalwhereby Rex Medical granted Angiotech an exclusive license to market anddistribute the Hemo-Stream catheter worldwide.
"The Hemo-Stream catheter is a great complement to the vascular graftbusiness we acquired from Edwards and our Vascular Wrap AV access trials whichare currently enrolling," said Dr. William Hunter, President and CEO ofAngiotech. "With over 500,000 End Stage Renal Disease patients in the U.S.,Angiotech is focused on the development and commercialization of innovativedialysis care products that improve the treatment options available tohemodialysis patients and vascular surgeons."
It is expected that Hemo-Stream catheters will be available for commercialsale in the U.S. later this year.
About Rex Medical, LP
Rex Medical, LP, based in Conshohocken, PA, is a privately held medicaldevice company specializing in the development, manufacturing and marketing ofminimally invasive medical devices targeted towards the cardiovascular, venousaccess, endosurgery and oncology markets.
Note on Forward Looking Statements
Statements contained in this press release that are not based onhistorical fact, including without limitation statements containing the words"believes," "may," "plans," "will," "estimate," "continue," "anticipates,""intends," "expects" and similar expressions, constitute "forward-lookingstatements" within the meaning of the U.S. Private Securities LitigationReform Act of 1995 and constitute "forward-looking information" within themeaning of applicable Canadian securities laws. All such statements are madepursuant to the "safe harbor" provisions of applicable securities legislation.Forward-looking statements in this release include but are not limited tostatements regarding; financial benefits to Angiotech that could potentiallybe realized from Angiotech's sale of the Hemo-Stream product, the ability ofAngiotech to commercialize the Hemo-Stream product and to develop andcommercialize any successive product lines, that a substantial market existsfor the product, and that the product will perform as expected. Suchforward-looking statements involve known and unknown risks, uncertainties andother factors that may cause the actual results, events or developments to bematerially different from any future results, events or developments expressedor implied by such forward-looking statements. Many such risks, uncertaintiesand other factors are taken into account as part of our assumptions underlyingthese forward-looking statements and include, among others, the following;general economic and business conditions, both nationally and in the regionsin which we operate; market demand; technological changes that could impactour existing products or our ability to develop and commercialize futureproducts; competition; existing governmental regulations and changes in, orthe failure to comply with, governmental regulations; decisions, and thetiming of decisions, made by health regulatory agencies regarding approval ofour technology and produc
